The pre-metastatic niche
Before a single cancer cell arrives, the primary tumour sends parcels ahead: tiny vesicles (exosomes) and hormones that recruit bone-marrow cells to a distant organ and remodel it into fertile soil. By the time the seed lands, the bed is already made.
Tumour-secreted factors (VEGF-A, PlGF, TNF, TGF-β, G-CSF, LOX) and exosomes prime distant sites: exosomal integrins address organs (α6β4/α6β1 to lung fibroblasts and epithelium, αvβ5 to liver Kupffer cells), exosomal MIF induces hepatic stellate cells to secrete fibronectin and TGF-β, and PDAC exosomes prepare liver niches; tumour-derived LOX crosslinks collagen; S100A8/A9 and SAA3 recruit VEGFR1+ haematopoietic progenitors, neutrophils and monocytes, which lay fibronectin, secrete MMP9, and increase vascular permeability. Hypoxia in the primary tumour amplifies the programme. The niche provides adhesion (fibronectin, periostin, tenascin C), survival signals, immune suppression (MDSCs, Treg), and later awakening cues (NETs, inflammation). Lymph nodes are similarly pre-conditioned (lymphangiogenesis via VEGF-C). Clinically the niche explains organ tropism and the benefit of adjuvant therapy; exosome profiling (integrin patterns, protein cargo) is being tested as a predictor of the site of relapse; LOX inhibitors and CXCR2/CCR2 blockade are experimental.
In one picture
A colonising power that sends engineers, seed and fertiliser to a distant shore before the settlers sail. The settlers (CTCs) that land where the soil has been prepared survive; the ones that land elsewhere starve.
Diagram
top- Adjuvant systemic therapy and ctDNA-guided escalation act during niche formation and early seeding
- Exosome and integrin profiling to predict organ of relapse (research); exosome-based therapeutics in early development
- LOX, CXCR2 and CCR2 inhibitors, and G-CSF neutralisation in models
- Anti-VEGF has not prevented metastasis in adjuvant trials (bevacizumab in colon and breast), a cautionary result
Pages like this
not linked directly; found by shared links- PathwayNutrient competition & metabolic immunosuppression
Shares Myeloid-derived suppressor cells (MDSCs), CSF1R, VHL / HIF oxygen sensing, HIF-2α and the tags mechanism, mechanics-atlas.
- PathwayThe angiogenic switch & tumour vessels
Shares CSF1R, VHL / HIF oxygen sensing, HIF-2α, Intravasation & circulating tumour cells and the tags mechanism, mechanics-atlas.
- PathwayMyeloid suppression: TAMs, MDSCs & don't-eat-me signals
Shares Myeloid-derived suppressor cells (MDSCs), CXCR4, CSF1R, VEGF / VEGFR and the tags mechanism, mechanics-atlas.
- PathwayCold tumours: immune deserts and exclusion
Shares CXCR4, CSF1R, Single-cell & spatial profiling, VEGF / VEGFR and the tags mechanism, mechanics-atlas.
- PathwayComplement in cancer
Shares Myeloid-derived suppressor cells (MDSCs), CSF1R and the tags mechanism, mechanics-atlas.
- PathwayDrug-tolerant persister cells
Shares Signatera, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing and the tags mechanism, mechanics-atlas.
- PathwaySynthetic lethality: paired dependencies
Shares VHL / HIF oxygen sensing, HIF-2α and the tags mechanism, mechanics-atlas.
- PathwayNK-cell recognition: missing self & stress ligands
Shares Intravasation & circulating tumour cells, Tumour dormancy and the tags mechanism, mechanics-atlas.